FOXO1 and TCF7L2 genes involved in metastasis and poor prognosis in clear cell renal cell carcinoma

Genes Chromosomes and Cancer

Volumn 49, Issue 4, 2010, Pages 379-389

  Kojima, Takahiro ^a   Shimazui, Toru ^a   Horie, Ryo ^a   Hinotsu, Shiro ^a   Oikawa, Takehiro ^a   Kawai, Koji ^a   Suzuki, Hideaki ^b   Meno, Kohji ^b   Akaza, Hideyuki ^a   Uchida, Kazuhiko ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Research Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR FKHR;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 13Q; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY;

ADULT; AGED; ANEUPLOIDY; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; CELL CYCLE; CELL GROWTH PROCESSES; CELL SURVIVAL; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DOXORUBICIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TCF TRANSCRIPTION FACTORS;

EID: 77949346468     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20750     Document Type: Article

References (38)

1. Arden KC. 2007. FoxOs in tumor suppression and stem cell maintenance. Cell 128:235-237.
2. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M, Jones KW, Wei W, Stratton MR, Futreal PA, Weber B, Shapero MH, Wooster R. 2004. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14:287-295.
3. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. 2004. Sarcomatoid renal cell carcinoma: An examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435-441.
5. Cifola I, Spinelli R, Beltrame L, Peano C, Fasoli E, Ferrero S, Bosari S, Signorini S, Rocco F, Perego R, Proserpio V, Raimondo F, Mocarelli P, Battaglia C. 2008. Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 7:6.
6. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944-13949.
7. Cindolo L, de la Taille A, Schips L, Zigeuner RE, Ficarra V, Tostain J, Artibani W, Gallo A, Salzano L, Patard JJ. 2005. Chromophobe renal cell carcinoma: Comprehensive analysis of 104 cases from multicenter European database. Urology 65:681-686.
8. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90.
9. Gunawan B, Huber W, Holtrup M, von Heydebreck A, Efferth T, Poustka A, Ringert RH, Jakse G, Fuzesi L. 2001. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: Gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 61:7731-7738.
10. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. 2005. Akt activation in renal cell carcinoma: Contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16:928-933.
11. Heinrichs S, Look AT. 2007. Identification of structural aberrations in cancer by SNP array analysis. Genome Biol 8:219.
12. Horiguchi A, Oya M, Uchida A, Marumo K, Murai M. 2003. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169:710-713.
13. Jiang F, Moch H, Richter J, Egenter C, Gasser T, Bubendorf L, Gschwind R, Sauter G, Mihatsch MJ. 1998. Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. J Pathol 185:382-388.
14. Jiang F, Desper R, Papadimitriou CH, Schaffer AA, Kallioniemi OP, Richter J, Schraml P, Sauter G, Mihatsch MJ, Moch H. 2000. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. Cancer Res 60:6503-6509.
15. Kim M, Katayose Y, Li Q, Rakkar AN, Li Z, Hwang SG, Katayose D, Trepel J, Cowan KH, Seth P. 1998. Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. Biochem Biophys Res Commun 253: 672-677.
16. Kojima T, Shimazui T, Hinotsu S, Joraku A, Oikawa T, Kawai K, Horie R, Suzuki H, Nagashima R, Yoshikawa K, Michiue T, Asashima M, Akaza H, Uchida K. 2009. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling. Oncogene 28:297-305.
17. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. 2005. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11:5128-5139.
18. Kovacs G, Frisch S. 1989. Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas. Cancer Res 49:651-659.
19. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B. 1997. The Heidelberg classification of renal cell tumours. J Pathol 183:131-133.
20. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790.
21. Lane BR, Li J, Zhou M, Babineau D, Faber P, Novick AC, Williams BR. 2009. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. J Urol 181:849-860.
22. Levy DA, Slaton JW, Swanson DA, Dinney CP. 1998. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163-1167.
23. Matsuzaki H, Dong S, Loi H, Di X, Liu G, Hubbell E, Law J, Berntsen T, Chadha M, Hui H, Yang G, Kennedy GC, Webster TA, Cawley S, Walsh PS, Jones KW, Fodor SP, Mei R. 2004. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat Methods 1:109-111.
24. Migita T, Oda Y, Naito S, Tsuneyoshi M. 2002. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 94:973-979.
25. Moch H, Presti JC, Jr., Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM. 1996. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56:27-30.
26. Monzon FA, Hagenkord JM, Lyons-Weiler MA, Balani JP, Parwani AV, Sciulli CM, Li J, Chandran UR, Bastacky SI, Dhir R. 2008. Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors. Mod Pathol 21:599-608.
27. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using highdensity oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079.
28. Pause A, Lee S, Lonergan KM, Klausner RD. 1998. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95:993-998.
29. Raghavan M, Lillington DM, Skoulakis S, Debernardi S, Chaplin T, Foot NJ, Lister TA, Young BD. 2005. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 65:375-378.
30. Reagan-Shaw S, Ahmad N. 2007. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: A target for the management of cancer. Toxicol Appl Pharmacol 224:360-368.
31. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
32. Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C. 2006. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 25:4361-4369.
33. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L. 2008. A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Proc Natl Acad Sci USA 105:9697-9702.
34. Teh MT, Blaydon D, Chaplin T, Foot NJ, Skoulakis S, Raghavan M, Harwood CA, Proby CM, Philpott MP, Young BD, Kelsell DP. 2005. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res 65:8597-8603.
35. Toma MI, Grosser M, Herr A, Aust DE, Meye A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, Baretton GB. 2008. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia 10:634-642.
36. Walther MM, Gnarra JR, Elwood L, Xu HJ, Florence C, Anglard P, Hu SX, King C, Trahan E, Hurley K, Sens D, Venzon D, Liu S, Jaffe GS, Benedict WF, Linehan MW. 1995. Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol 153:2050-2054.
37. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro OM, Karlan B, Kaufman B, Koeffler HP, Rubinek T. 2008. Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094-8105.
38. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, Hacker G. 2007. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: Evidence for contribution to apoptosis resistance. Oncogene 26:7038-7048.